

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity ZELDA THERAPEUTICS LIMITED</b>	
<b>ABN</b>	27 103 782 378

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Jason Peterson
<b>Date of last notice</b>	7 December 2018

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<ul style="list-style-type: none"> <li>i. Jason Peterson and Lisa Peterson &lt;J&amp;L Peterson S/F A/C&gt; (Beneficiary)</li> <li>ii. Celtic Capital Pty Ltd &lt;The Celtic Capital A/C&gt; (Director/Shareholder)</li> <li>iii. Celtic Capital Pte Ltd &lt;Investment 1 A/C&gt; (Director/Shareholder)</li> <li>iv. Professional Payment Services Pty Ltd (Director/Shareholder)</li> <li>v. CPS Capital Group Pty Ltd ('CPS') (Director/Shareholder)</li> <li>vi. Wicklow Capital Pty Ltd &lt;Tipperary A/C&gt; (Director/Shareholder)</li> <li>vii. Sunset Capital Management Pty Ltd &lt;Sunset Superfund&gt; (Director/Shareholder)</li> </ul>
<b>Date of change</b>	13 December 2018

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held prior to change</b>	<ul style="list-style-type: none"> <li>i. 52,459,017 ordinary shares</li> <li>i. 8,000,000 options (\$0.03125; 17/11/2021)</li> <li>ii. 11,200,000 ordinary shares</li> <li>iii. 5,800,000 ordinary shares</li> <li>iv. 538,231 ordinary shares</li> <li>v. 4,800,000 ordinary shares</li> </ul>
<b>Class</b>	Ordinary shares
<b>Number acquired</b>	52,459,017
<b>Number disposed</b>	52,459,017
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil
<b>No. of securities held after change</b>	<ul style="list-style-type: none"> <li>i. 8,000,000 options (\$0.03125; 17/11/2021)</li> <li>ii. 11,200,000 ordinary shares</li> <li>iii. 5,800,000 ordinary shares</li> <li>iv. 538,231 ordinary shares</li> <li>v. 3,157,895 ordinary shares</li> <li>vi. 1,642,105 ordinary shares</li> <li>vii. 52,459,017 ordinary shares</li> </ul>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Internal restructure. No ultimate change in Director interest.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

+ See chapter 19 for defined terms.